Literature DB >> 30927972

Clinicopathological aspects of therapy-related acute myeloid leukemia and myelodysplastic syndrome.

Chong Chyn Chua1, Shaun Fleming2, Andrew H Wei3.   

Abstract

Therapy-related myeloid neoplasm (t-MN) is a rare but devastating consequence of chemotherapy and/or radiotherapy used for the treatment of solid cancers and various hematologic malignancies. Our current understanding of the etiology is that hematopoietic clones that are contemporaneous with the primary cancer and resistant to the cytotoxic exposure have the potential to undergo selective expansion and transformation to t-MN. Consequently, a large proportion of cases are associated with adverse risk factors, resulting in limited effective treatment options. Despite the emergence of some therapies with promising activity in t-MN, most effects are short-lived and allogeneic stem cell transplantation remains the only curative option for eligible patients. This review summarizes the current literature on t-AML and t-MDS, with the aim of providing practical recommendations on the clinical evaluation and management of these conditions. Crown
Copyright © 2019. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clonal hematopoiesis; TP53; Therapy-related myeloid neoplasm; t-AML; t-MDS

Mesh:

Year:  2019        PMID: 30927972     DOI: 10.1016/j.beha.2019.02.007

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  4 in total

1.  The role of clonal hematopoiesis as driver of therapy-related myeloid neoplasms after autologous stem cell transplantation.

Authors:  Doriana Gramegna; Diego Bertoli; Chiara Cattaneo; Camillo Almici; Alessandro Re; Angelo Belotti; Erika Borlenghi; Gaetana Lanzi; Silvana Archetti; Rosanna Verardi; Duilio Brugnoni; Margherita Sciumè; Rosa Daffini; Aldo M Roccaro; Alessandra Tucci; Giuseppe Rossi
Journal:  Ann Hematol       Date:  2022-04-05       Impact factor: 3.673

2.  Can synthetic lethality approach be used with DNA repair genes for primary and secondary MDS?

Authors:  Howard Lopes Ribeiro Junior; Roberta Taiane Germano de Oliveira; Daniela de Paula Borges; Marília Braga Costa; Izabelle Rocha Farias; Antônio Wesley Araújo Dos Santos; Silvia Maria Meira Magalhães; Ronald Feitosa Pinheiro
Journal:  Med Oncol       Date:  2019-10-30       Impact factor: 3.064

3.  [Therapy-related acute myeloid leukemia with t(9;22)(q34;q11) and t(16;21)(q24;q22) double translocation: a case report and literature review].

Authors:  X Y Dong; Y L Li; C Y Wu; W Cheng; B J Shang; L Zhang; L N Cheng; Z M Zhu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-11-14

Review 4.  TP53 in Myelodysplastic Syndromes: Recent Biological and Clinical Findings.

Authors:  Cosimo Cumbo; Giuseppina Tota; Luisa Anelli; Antonella Zagaria; Giorgina Specchia; Francesco Albano
Journal:  Int J Mol Sci       Date:  2020-05-13       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.